ImmunityBio (IBRX) Return on Invested Capital (2015 - 2026)

ImmunityBio (IBRX) has 12 years of Return on Invested Capital data on file, last reported at 0.01% in Q1 2026.

• Quarterly Return on Invested Capital rose 6.0% year-over-year to 0.01% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.01% (up 6.0% YoY) and the FY2025 annual result came in at 0.03%, changed N/A from the prior year.
• Return on Invested Capital climbed to 0.01% in Q1 2026 per IBRX's latest filing, from 0.01% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.04% in Q2 2025 and bottomed at 0.05% in Q1 2025.
• The 5-year median for Return on Invested Capital is 0.01% (2024), against an average of 0.01%.
• The widest annual swing landed in 2025, when Return on Invested Capital decreased 6 bps; it then climbed 6 bps in 2026.
• Tracing IBRX's Return on Invested Capital over 5 years: stood at 0.01% in 2022, then gained by 7 bps to 0.01% in 2023, then dropped by 19 bps to 0.01% in 2024, then slipped by 10 bps to 0.01% in 2025, then gained by 2 bps to 0.01% in 2026.
• Per Business Quant, the three latest IBRX Return on Invested Capital figures stand at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025).

Peer Comparison